Abstract | INTRODUCTION: METHODS: Our experimental protocol consisted of administration of nicotine (2.5 mg/kg, subcutaneously), 4 times daily for 7 days. In order to precipitate nicotine withdrawal, mice were given 1 injection of mecamylamine (3 mg/kg, intraperitoneally), 1 hr after the last nicotine injection on the test day (Day 8). Behavioral observations were made for a period of 30 min immediately after mecamylamine treatment. Withdrawal syndrome was quantitated in terms of a composite withdrawal severity score (WSS), and withdrawal syndrome-related anxiety was assessed by elevated plus maze test results. RESULTS:
SU-6656 markedly and dose dependently (p < .01) attenuated mecamylamine-induced experimental nicotine withdrawal syndrome in mice measured in terms of WSS and anxiety score. CONCLUSIONS: Thus, it is suggested that src kinase is involved in the development of nicotine dependence-induced precipitation of its withdrawal syndrome and thus may serve as a viable pharmacological target to tackle the problem of nicotine addiction.
|
Authors | Ashish K Rehni, Thakur Gurjeet Singh, Sandeep Arora |
Journal | Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
(Nicotine Tob Res)
Vol. 14
Issue 4
Pg. 407-14
(Apr 2012)
ISSN: 1469-994X [Electronic] England |
PMID | 22102627
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indoles
- Narcotic Antagonists
- SU 6656
- Sulfonamides
- Mecamylamine
- Nicotine
- src-Family Kinases
|
Topics |
- Animals
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Female
- Indoles
(administration & dosage, pharmacology, therapeutic use)
- Injections, Intraperitoneal
- Injections, Subcutaneous
- Male
- Mecamylamine
(administration & dosage, pharmacology)
- Mice
- Narcotic Antagonists
(pharmacology)
- Nicotine
(administration & dosage, pharmacology)
- Substance Withdrawal Syndrome
(drug therapy)
- Sulfonamides
(administration & dosage, pharmacology, therapeutic use)
- Tobacco Use Disorder
(drug therapy)
- src-Family Kinases
(antagonists & inhibitors)
|